MCID: HST010
MIFTS: 48

Histiocytosis

Categories: Immune diseases

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Name: Histiocytosis 12 54 43 15 71
Hand Schuller Christian Disease 12
Hand-Schüller-Christian Disease 74
Histiocytosis, Langerhans-Cell 71
Chronic Histiocytosis X 12
Histiocytic Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3405
MeSH 43 D015614
NCIt 49 C3106
SNOMED-CT 67 60657004
UMLS 71 C0019618 C0019621 C0398597

Summaries for Histiocytosis

Disease Ontology : 12 A lymphatic system disease that is characterized by an excessive number of histiocytes.

MalaCards based summary : Histiocytosis, also known as hand schuller christian disease, is related to histiocytosis-lymphadenopathy plus syndrome and alk+ histiocytosis. An important gene associated with Histiocytosis is SLC29A3 (Solute Carrier Family 29 Member 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Levoleucovorin and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and lymph node, and related phenotypes are Misorientated spindle and hematopoietic system

Wikipedia : 74 Hand-Schüller-Christian disease is associated with multifocal Langerhans cell... more...

Related Diseases for Histiocytosis

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 967)
# Related Disease Score Top Affiliating Genes
1 histiocytosis-lymphadenopathy plus syndrome 34.7 SLC29A3 SERPINA3 CD1C CD1A
2 alk+ histiocytosis 34.1 CD207 CD1A ALK
3 erdheim-chester disease 33.3 SERPINA3 NRAS CD1C CD1A BRAF
4 primary cutaneous anaplastic large cell lymphoma 32.8 PTPRC ALK
5 rosai-dorfman disease 32.8 STAB1 SLC29A3 S100B MAP2K1 CD163 BRAF
6 juvenile xanthogranuloma 32.6 SERPINA3 S100B CD1C CD1A BRAF
7 interdigitating dendritic cell sarcoma 32.5 SERPINA3 CD1C CD1A
8 dendritic cell tumor 32.5 S100B PTPRC CD207 CD1A
9 non-langerhans-cell histiocytosis 32.5 U2AF1 SERPINA3 IL1RN CD207 CD1C CD1A
10 fibrosarcoma of bone 32.3 TNFRSF8 SERPINA3 CD1C CD1A
11 reticulohistiocytic granuloma 32.2 SERPINA3 CD207 CD1C CD1A CD163
12 langerhans cell sarcoma 31.7 TNFRSF8 CD207 CD1C CD1A CD163
13 langerhans cell histiocytosis 31.5 U2AF1 S100B PTPRC NRAS MAP2K1 ITGAX
14 exophthalmos 31.0 CD207 CD1C CD1A
15 omenn syndrome 30.9 TNFRSF8 SERPINA3 PTPRC IL1RN CCR6
16 histiocytic sarcoma 30.8 CD163 BRAF
17 seborrheic dermatitis 30.3 CD207 CD1C CD1A CCR6
18 differentiated thyroid carcinoma 30.3 NRAS BRAF ALK
19 polyclonal hypergammaglobulinemia 30.1 SLC29A3 SERPINA3 CD1C CD1A
20 hairy cell leukemia 30.1 U2AF1 MAP2K1 ITGAX BRAF
21 malignant fibrous histiocytoma 30.1 SERPINA3 S100B PTPRC
22 leprosy 3 30.1 CD1C CD1A CCR6
23 marginal zone b-cell lymphoma 30.0 U2AF1 TNFRSF8 CCR6
24 monoclonal gammopathy of uncertain significance 30.0 U2AF1 PTPRC CCR6
25 lichen nitidus 30.0 CD1C CD1A
26 lethal midline granuloma 30.0 TNFRSF8 SERPINA3
27 lymphomatoid papulosis 30.0 TNFRSF8 ALK
28 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.0 TNFRSF8 PTPRC
29 rhinoscleroma 29.9 SLC29A3 CD1C CD1A
30 fibrous histiocytoma 29.9 SERPINA3 S100B CD163 ALK
31 adenocarcinoma 29.9 U2AF1 MAP2K1 BRAF ARAF ALK
32 sarcoidosis 1 29.9 SERPINA3 PTPRC IL1RN CCR6
33 lymphoma, hodgkin, classic 29.8 TNFRSF8 PTPRC CCR6 ALK
34 spongiotic dermatitis 29.8 CD1C CD1A
35 lymph node disease 29.8 SERPINA3 PTPRC ITGAX CCR6
36 lymphoma 29.8 TNFRSF8 PTPRC NRAS MAP2K1 CCR6 BRAF
37 amelanotic melanoma 29.8 SERPINA3 S100B BRAF
38 necrobiosis lipoidica 29.7 CD1A CD163
39 acute promyelocytic leukemia 29.7 U2AF1 PTPRC NRAS MAP2K1 ITGAX
40 granulomatous dermatitis 29.6 CD1C CD163 BRAF
41 orbital cancer 29.6 CD1C CD1A
42 demyelinating disease 29.5 U2AF1 SERPINA3 PTPRC CCR6
43 reticulosarcoma 29.5 TNFRSF8 SERPINA3 PTPRC ALK
44 bone lymphoma 29.5 TNFRSF8 PTPRC ALK
45 chediak-higashi syndrome 29.4 SERPINA3 ITGAX CD207 CCR6
46 systemic mastocytosis 29.4 U2AF1 TNFRSF8 NRAS
47 leiomyosarcoma 29.4 SERPINA3 S100B PTPRC
48 reticulum cell sarcoma 29.4 TNFRSF8 PTPRC
49 benign giant cell tumor 29.3 TNFRSF8 SERPINA3 PTPRC
50 mycosis fungoides 29.3 TNFRSF8 CD1C CD1A CCR6 ALK

Graphical network of the top 20 diseases related to Histiocytosis:



Diseases related to Histiocytosis

Symptoms & Phenotypes for Histiocytosis

GenomeRNAi Phenotypes related to Histiocytosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Misorientated spindle GR00256-A 8.8 ALK ARAF BRAF

MGI Mouse Phenotypes related to Histiocytosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 ARAF BRAF CCR6 CD101 CD163 CD207
2 immune system MP:0005387 9.4 ARAF BRAF CCR6 CD101 CD163 CD207

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
2
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
3
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
4
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
5
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
6
Indomethacin Approved, Investigational Phase 2, Phase 3 53-86-1 3715
7
Zoledronic Acid Approved Phase 3 118072-93-8 68740
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
9
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
10 Micronutrients Phase 3
11 Trace Elements Phase 3
12 Vitamins Phase 3
13 Antidotes Phase 3
14 Nutrients Phase 3
15 Antiviral Agents Phase 2, Phase 3
16 Analgesics, Non-Narcotic Phase 2, Phase 3
17 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
18 Immunoglobulins Phase 2, Phase 3
19 2-chloro-3'-deoxyadenosine Phase 2, Phase 3
20 Antibodies Phase 2, Phase 3
21 Immunoglobulins, Intravenous Phase 2, Phase 3
22 Rho(D) Immune Globulin Phase 2, Phase 3
23 Cyclooxygenase Inhibitors Phase 2, Phase 3
24 gamma-Globulins Phase 2, Phase 3
25 Tocolytic Agents Phase 2, Phase 3
26 Analgesics Phase 3
27 Pharmaceutical Solutions Phase 3
28 Anesthetics Phase 3
29 Diphosphonates Phase 3
30 Immunologic Factors Phase 2, Phase 3
31 Immunosuppressive Agents Phase 2, Phase 3
32 Alkylating Agents Phase 2, Phase 3
33 Thymoglobulin Phase 2, Phase 3
34
Thioguanine Approved Phase 2 154-42-7 2723601
35
Etanercept Approved, Investigational Phase 2 185243-69-0
36
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
37
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
38
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
39 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
40
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
41
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 27284 23925
42
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
43
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
46
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
49
Olaparib Approved Phase 2 763113-22-0 23725625
50
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Completed NCT00488605 Phase 3 Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
3 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Recruiting NCT02205762 Phase 2, Phase 3 Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
4 Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115) Recruiting NCT02670707 Phase 3 Cytarabine;Vinblastine/prednisone
5 Cobimetinib for BRAF-wild-type Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study Recruiting NCT04007848 Phase 3 Cobimetinib;Placebo oral tablet
6 Non-inferiority Trial of Three Cycles of Zoledronic Acid Versus Percutaneous Thermal Ablation in Osteoid Osteoma Suspended NCT02739555 Phase 3 Acide Zoledronique
7 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
8 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
9 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
10 Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH) Completed NCT00588536 Phase 2 Methotrexate;6-Thioguanine;Leucovorin Calcium
11 Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis Completed NCT02389400 Phase 2 methotrexate
12 A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis Completed NCT01395004 Phase 2 GSK2110183
13 Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE) Completed NCT00048373 Phase 2 Etanercept
14 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
15 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
16 A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Completed NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
17 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Completed NCT00145626 Phase 2 Chemotherapy and antibodies
18 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
19 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
20 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Recruiting NCT02425904 Phase 2 Clofarabine
21 Cytarabine Monotherapy for Adult Patients With Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04121819 Phase 2 Cytarabine
22 Thalidomide, Cyclophosphamide and Dexamethasone for Adult Patients With Recurrent/Refractory Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04120519 Phase 2 thalidomide combined with dexamethasone and cyclophosphamide
23 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
24 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
25 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
26 Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial Recruiting NCT03270020 Phase 2 Denosumab 70 MG/ML [Xgeva]
27 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
28 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
29 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Recruiting NCT03213665 Phase 2 Tazemetostat
30 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
31 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
32 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Recruiting NCT03698994 Phase 2 Ulixertinib
33 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
34 Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment Recruiting NCT03096782 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
35 The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation Recruiting NCT03585686 Phase 2 Vemurafenib;Cytarabine;2-chlorodeoxyadenosine
36 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
37 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease Recruiting NCT02061800 Phase 1, Phase 2 Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
38 Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders Recruiting NCT02649972 Phase 2 Cobimetinib
39 Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function Active, not recruiting NCT01473797 Phase 2 Cladribine
40 A Phase II Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
41 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease Active, not recruiting NCT01966367 Phase 1, Phase 2
42 An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations Active, not recruiting NCT02124772 Phase 1, Phase 2 Trametinib;Dabrafenib
43 Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma Active, not recruiting NCT01887522 Phase 2 Vinblastine + Nilotinib;Vinblastine
44 A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. Not yet recruiting NCT04079179 Phase 2 Cobimetinib
45 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Not yet recruiting NCT04320888 Phase 2 Selpercatinib
46 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Not yet recruiting NCT04284774 Phase 2 Tipifarnib
47 Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis Terminated NCT00618540 Phase 2 fludarabine phosphate;melphalan
48 Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders Terminated NCT01050439 Phase 2
49 A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors Terminated NCT02012231 Phase 1, Phase 2 PLX8394
50 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis Withdrawn NCT01796405 Phase 2 Clofarabine

Search NIH Clinical Center for Histiocytosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Etoposide
etoposide phosphate
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: histiocytosis

Genetic Tests for Histiocytosis

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

40
Bone, Lung, Lymph Node, Skin, Thyroid, Bone Marrow, Liver

Publications for Histiocytosis

Articles related to Histiocytosis:

(show top 50) (show all 8837)
# Title Authors PMID Year
1
[Eosinophilic granuloma of the temporal bone. Case report and literature review]. 54 61
12717600 2003
2
Oral submucosal dendrocytes: factor XIIIa+ and CD34+ dendritic cell populations in normal tissue and fibrovascular lesions. 61 54
1282135 1992
3
Multisystem Langerhans cell histiocytosis in an adult non-smoker treated with steroid therapy. 61
32547768 2020
4
Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions. 61
32530258 2020
5
Long-term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan. 61
32383820 2020
6
Solitary adult xanthogranuloma in external auditory canal: Cyto-histopathological correlation of an uncommon entity at an uncommon site. 61
32275346 2020
7
Langerhans cell histiocytosis of the thyroid together with papillary thyroid carcinoma. 61
32314308 2020
8
Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. 61
31896812 2020
9
Mutation in the SLC29A3 Gene in an Egyptian Patient with H Syndrome: A Case Report and Review of Literature. 61
32341814 2020
10
Localized Crystal-Storing Histiocytosis Involving Lower Rectum. 61
31500480 2020
11
Unilateral Periocular Intralymphatic Histiocytosis, Associated With Rosacea (Morbihan Disease). 61
31764086 2020
12
Successful Treatment of Large Cutaneous Facial Rosai-Dorfman Disease Using Combination of Subtotal Resection and ALA-PDT: A Case Report. 61
32562733 2020
13
Extra Nodal Rosai-Dorfman Disease Originating in the Nasal and Paranasal Complex and Gnathic Bones: A Systematic Analysis of Seven Cases and Review of Literature. 61
31368076 2020
14
Complete Microsurgical Resection of Large Retrochiasmatic Hypothalamic Craniopharyngioma by Transpetrosal Approach: 2-Dimensional Operative Video. 61
31538198 2020
15
Management of severe pulmonary Langerhans cell histiocytosis in children. 61
32511892 2020
16
Acquired Von Willebrand Syndrome Secondary to Langerhans Cell Histiocytosis. 61
31900848 2020
17
[Pulmonary Langerhans cell histiocytosis: discussion of a case]. 61
32486555 2020
18
Cyclin D1 and BRAF V600E immunohistochemical staining in pulmonary Langerhans cell histiocytosis. 61
31965621 2020
19
Langerhans cell histiocytosis confined to extrahepatic bile duct causing sclerosing cholangitis in child: a case report. 61
32548778 2020
20
[Solitary Langerhans cell histiocytosis of the stomach: report of a case]. 61
32486547 2020
21
CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis. 61
32238382 2020
22
Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience. 61
32514929 2020
23
Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. 61
31407478 2020
24
Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity. 61
32283322 2020
25
Aggressive Langerhans cell histiocytosis transformation of T cell acute lymphoblastic leukemia detected on 18F-FDG PET/CT. 61
32504290 2020
26
Refractory Inflammatory Bowel Disease Associated With Sclerosing Cholangitis, Diabetes Insipidus, and Myeloid Neoplasm: Langerhans Cell Histiocytosis Was Hiding Since the Beginning. 61
32530029 2020
27
Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. 61
32191819 2020
28
Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim-Chester disease: case-based review. 61
32572610 2020
29
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. 61
32349088 2020
30
Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. 61
32052319 2020
31
Smoking-associated interstitial lung disease: update and review. 61
32379511 2020
32
Gastric crystal-storing histiocytosis with concomitant mucosa-associated lymphoid tissue lymphoma. 61
32434299 2020
33
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. 61
32187362 2020
34
A case of Erdheim-Chester disease initially mistaken for retroperitoneal lymphoma. 61
32211088 2020
35
Postmortem findings in Magellanic penguins (Spheniscus magellanicus) caught in a drift gillnet. 61
32448250 2020
36
MR imaging of cerebral involvement of Rosai-Dorfman disease: a single-centre experience with review of the literature. 61
32458270 2020
37
Cutaneous intralymphatic histiocytosis associated with breast and orthopedic surgery. 61
32396263 2020
38
Persistent Laryngeal Swelling Caused by Primary Intralymphatic Histiocytosis. 61
32437570 2020
39
Intravascular histiocytosis: case report of a rare disease probably associated with silicone breast implant. 61
32303432 2020
40
Agminated flexural melanocytic nevus associated with Langerhans cell histiocytosis. 61
32400018 2020
41
Adult Langerhans cell histiocytosis with recurrent vulvar ulcers. 61
32275097 2020
42
Oral manifestations of Langerhans cell histiocytosis with unusual histomorphologic features. 61
32454442 2020
43
Localized Acral Sclerosing Langerhans Cell Histiocytosis: A New Form of Presentation of Cutaneous Langerhans Cell Histiocytosis. 61
31725482 2020
44
Prevalence, Epidemiology, Etiology, and Sensitivity of Invasive Bacterial Infections in Pediatric Patients Undergoing Oncological Treatment: A Multicenter Nationwide Study. 61
32434455 2020
45
BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. 61
32171112 2020
46
Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis. 61
32372223 2020
47
Association Between High-Grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing. 61
32374348 2020
48
Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study. 61
32395858 2020
49
The combination of methotrexate and cytosine arabinoside in newly diagnosed adult Langerhans cell histiocytosis: a prospective phase II interventional clinical trial. 61
32423455 2020
50
Langerhans cell histiocytosis of the shoulder girdle, pelvis and extremities: a review of radiographic and MRI features in 85 cases. 61
32451558 2020

Variations for Histiocytosis

Expression for Histiocytosis

Search GEO for disease gene expression data for Histiocytosis.

Pathways for Histiocytosis

Pathways related to Histiocytosis according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNFRSF8 SERPINA3 S100B PTPRC NRAS MAP2K1
2
Show member pathways
13.3 TNFRSF8 NRAS MAP2K1 ITGAX IL1RN BRAF
3
Show member pathways
12.81 NRAS MAP2K1 ITGAX BRAF ARAF
4 12.79 NRAS MAP2K1 BRAF ARAF ALK
5
Show member pathways
12.75 NRAS MAP2K1 ITGAX BRAF ARAF
6
Show member pathways
12.62 NRAS MAP2K1 BRAF ARAF ALK
7 12.57 NRAS MAP2K1 ITGAX BRAF ARAF
8
Show member pathways
12.37 NRAS MAP2K1 BRAF ARAF
9
Show member pathways
12.36 PTPRC NRAS MAP2K1 BRAF
10
Show member pathways
12.28 NRAS MAP2K1 BRAF ARAF
11 12.25 NRAS MAP2K1 BRAF ARAF
12
Show member pathways
12.25 NRAS MAP2K1 BRAF ARAF
13
Show member pathways
12.25 NRAS MAP2K1 ITGAX BRAF ARAF ALK
14
Show member pathways
12.24 NRAS MAP2K1 BRAF ARAF
15
Show member pathways
12.23 NRAS MAP2K1 BRAF ARAF
16
Show member pathways
12.17 NRAS MAP2K1 ITGAX BRAF ARAF
17
Show member pathways
12.11 NRAS MAP2K1 BRAF ARAF
18
Show member pathways
12.07 NRAS MAP2K1 BRAF ARAF
19
Show member pathways
12.01 NRAS MAP2K1 BRAF ARAF
20
Show member pathways
12 NRAS MAP2K1 BRAF ARAF
21 11.91 PTPRC ITGAX CD1C CD163
22 11.9 NRAS MAP2K1 BRAF ARAF
23 11.88 NRAS MAP2K1 BRAF ARAF
24 11.86 NRAS MAP2K1 BRAF ARAF
25 11.83 MAP2K1 BRAF ARAF
26
Show member pathways
11.83 NRAS MAP2K1 BRAF ARAF
27
Show member pathways
11.78 PTPRC NRAS MAP2K1 BRAF ARAF
28 11.74 PTPRC CD101 CCR6
29 11.72 MAP2K1 BRAF ARAF
30
Show member pathways
11.68 NRAS MAP2K1 BRAF ARAF
31 11.6 NRAS MAP2K1 BRAF ARAF
32
Show member pathways
11.52 NRAS MAP2K1 BRAF ARAF
33 11.47 MAP2K1 BRAF ARAF
34 11.45 NRAS MAP2K1 BRAF ARAF
35 11.26 NRAS MAP2K1 BRAF ARAF
36 11.25 NRAS MAP2K1 BRAF
37 10.97 PTPRC ITGAX CD207 CD1C CD1A CD163
38 10.93 NRAS MAP2K1 BRAF ARAF ALK

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 STAB1 PTPRC CD1C CD1A CD163 CCR6
2 plasma membrane GO:0005886 9.53 TNFRSF8 STAB1 SLC29A3 PTPRC NRAS MAP2K1
3 external side of plasma membrane GO:0009897 9.43 PTPRC ITGAX CD1C CD1A CD163 CCR6

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.67 NRAS MAP2K1 BRAF ARAF
2 regulation of axon regeneration GO:0048679 9.32 MAP2K1 BRAF
3 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.26 CD1C CD1A
4 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.16 CD1C CD1A
5 positive regulation of T cell mediated cytotoxicity GO:0001916 9.13 PTPRC CD1C CD1A
6 DN2 thymocyte differentiation GO:1904155 8.62 PTPRC CCR6

Molecular functions related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 U2AF1 TNFRSF8 STAB1 SLC29A3 SERPINA3 S100B
2 lipopeptide binding GO:0071723 9.26 CD1C CD1A
3 exogenous lipid antigen binding GO:0030884 8.96 CD1C CD1A
4 endogenous lipid antigen binding GO:0030883 8.62 CD1C CD1A

Sources for Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....